Randomized evidence has shown that continuous glucose monitoring (CGM) can improve glycemic control in adults with type 2 diabetes treated with basal insulin, particularly when the technology is integrated into routine clinical follow-up. CGM provides trend information, time-in-range data and alerts that are not available from intermittent finger-stick measurements alone. For internists, this can change the conversation from a small number of isolated glucose readings to an ongoing profile of glycemic variability and treatment response. The value is greatest when patients understand how to interpret trends and clinicians have a plan for reviewing and acting on the data. CGM does not automatically improve outcomes if the information is not translated into treatment decisions, and access, affordability and digital literacy remain barriers. In older adults or patients with complex regimens, individualized alarm settings and education are particularly important. The broader significance is that diabetes technology increasingly functions as a clinical-management tool rather than merely a monitoring device. This aligns with APICON's focus on wearables and digital health, where the central question is how technology improves decisions and patient behavior rather than simply generating more data.